These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 4364044)

  • 1. Action of two hypothalamic factors (TRH, MIF) and of angiotensin II on the behavioral effects of L-DOPA and 5-hydroxytryptophan in mice.
    Huidobro-Toro JP; De Carolis AS; Longo VG
    Pharmacol Biochem Behav; 1974; 2(1):105-9. PubMed ID: 4364044
    [No Abstract]   [Full Text] [Related]  

  • 2. Intensification of central catecholaminergin and serotonergic processes by the hypothalamic factors MIF and TRF and by angiotensin II.
    Huidobro-Toro JP; Scotti de Carolis A; Longo VG
    Pharmacol Biochem Behav; 1975; 3(2):235-42. PubMed ID: 238221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyrotropin releasing hormone: enhancement of dopa activity by a hypothalamic hormone.
    Plotnikoff NP; Prange AJ; Breese GR; Anderson MS; Wilson IC
    Science; 1972 Oct; 178(4059):417-8. PubMed ID: 4627781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thyrotropin releasing hormone (TRH): DOPA potentiation and biogenic amine studies.
    Plotnikoff NP; Breese GR; Prange AJ
    Pharmacol Biochem Behav; 1975; 3(4):665-70. PubMed ID: 810812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An investigation on the behavioral and hypothermic effects of yohimbine: interaction with drugs affecting central and peripheral monoamines.
    Papeschi R
    Arch Int Pharmacodyn Ther; 1974 Mar; 208(1):61-80. PubMed ID: 4276928
    [No Abstract]   [Full Text] [Related]  

  • 6. Prolyl-leucyl-glycine amide (PLG) and thyrotropin-releasing hormone (TRH): DOPA potentiation and biogenic amine studies.
    Plotnikoff NP
    Prog Brain Res; 1975; 42():11-23. PubMed ID: 730
    [No Abstract]   [Full Text] [Related]  

  • 7. DOPA potentiation by a hypothalamic factor, MSH release-inhibiting hormone (MIF).
    Plotnikoff NP; Kastin AJ; Anderson MS; Schally AV
    Life Sci I; 1971 Nov; 10(22):1279-83. PubMed ID: 4947365
    [No Abstract]   [Full Text] [Related]  

  • 8. A study of the central effects of 5,6-dihydroxytryptamine.
    Longo VG; Scotti de Carolis A; Liuzzi A; Massotti M
    Adv Biochem Psychopharmacol; 1974; 10():109-20. PubMed ID: 4546514
    [No Abstract]   [Full Text] [Related]  

  • 9. Studies on the inhibition of oxotremorine induced tremor by a melanocyte-stimulating hormone release-inhibiting factor, thyrotropin releasing hormone and related peptides.
    Castensson S; Sievertsson H; Lindeke B; Sum CY
    FEBS Lett; 1974 Aug; 44(1):101-5. PubMed ID: 4212370
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of biogenic amines and TRH on release of prolactin and TSH in the rat.
    Chen HJ; Meites J
    Endocrinology; 1975 Jan; 96(1):10-4. PubMed ID: 803259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on the influence of biogenic amines and psychoactive drugs on the prognostic value of the TRH stimulation test in endogenous depression.
    Kirkegaard C; Bjørum N; Cohn D; Faber J; Lauridsen UB; Nekup J
    Psychoneuroendocrinology; 1977; 2(2):131-6. PubMed ID: 414252
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute and long-term effects of thyrotropin releasing hormone on behavior mediated by dopaminergic and cholinergic activities in mice.
    Ushijima I; Yamada K; Furukawa T
    Psychopharmacology (Berl); 1984; 82(4):301-5. PubMed ID: 6427818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of aggressiveness-stereotype complex induced in mice by amphetamine or nialamide and L-dopa.
    Roliński Z
    Pol J Pharmacol Pharm; 1973; 25(6):551-8. PubMed ID: 4799834
    [No Abstract]   [Full Text] [Related]  

  • 14. Hypothalamic releasing factors and Parkinson disease.
    Chase TN; Woods AC; Lipton MA; Morris CE
    Arch Neurol; 1974 Jul; 31(1):55-6. PubMed ID: 4209275
    [No Abstract]   [Full Text] [Related]  

  • 15. Synthetic MIF analogues. Part II: Dopa potentiation and fluphenazine antagonism.
    Voith K
    Arzneimittelforschung; 1977; 27(12):2290-3. PubMed ID: 23795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth hormone release inhibiting hormone: neuropharmacological studies.
    Plotnikoff NP; Kastin AJ; Schally AV
    Pharmacol Biochem Behav; 1974; 2(5):693-6. PubMed ID: 4610595
    [No Abstract]   [Full Text] [Related]  

  • 17. Melanocyte-stimulating hormone and parkinsonism: the role of hypothalamic releasing factors.
    Sandler M; Goodwin BL; Leask BG; Ruthven CR
    Lancet; 1973 Mar; 1(7803):612. PubMed ID: 4120682
    [No Abstract]   [Full Text] [Related]  

  • 18. Time and dose influences on the behavioral effects of L-DOPA and 5-hydroxytryptophan after inhibition of extracerebral decarboxylase.
    Gronan RJ
    Pharmacol Biochem Behav; 1975; 3(2):161-6. PubMed ID: 1079949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MSH-release inhibiting factors: recent studies.
    Kastin AJ; Plotnikoff NP; Viosca S; Anderson MS; Schally AV
    Yale J Biol Med; 1973 Dec; 46(5):617-22. PubMed ID: 4591788
    [No Abstract]   [Full Text] [Related]  

  • 20. Mechanisms of tremor induction by harmine.
    Kelly DM; Naylor RJ
    Eur J Pharmacol; 1974 Jun; 27(1):14-24. PubMed ID: 4277567
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.